NasdaqGS:UTHRBiotechs
United Therapeutics Phase 3 Lung Data Could Reshape Pulmonary Franchise Outlook
United Therapeutics (NasdaqGS:UTHR) plans to present new phase 3 clinical data for Tyvaso (inhaled treprostinil for idiopathic pulmonary fibrosis) and ralinepag (for pulmonary arterial hypertension) at the upcoming American Thoracic Society International Conference.
The company will also share additional research across multiple lung diseases, highlighting a broad set of respiratory-focused findings at the meeting.
United Therapeutics focuses on therapies for serious pulmonary and...